Search research articles
Contact Us
Filters
Showing results (91-100 of 108) with videos related to
Page
of 11
Sort By:
Nordic Journal of Psychiatry
|
June 19, 2004
Coercion in psychiatric care - patients' and relatives' experiences from four Swedish psychiatric services
Lars Kjellin, Kristina Andersson, Erik Bartholdson, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
November 5, 2005
Therapeutic efficacy and tumor dose estimations in radioimmunotherapy of intraperitoneally growing OVCAR-3 cells in nude mice with (211)At-labeled monoclonal antibody MX35
Jörgen Elgqvist, Håkan Andersson, Tom Bäck, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
July 7, 2022
Estimating the Risk for Secondary Cancer After Targeted α-Therapy with <sup>211</sup>At Intraperitoneal Radioimmunotherapy
Erik Leidermark, Andreas Hallqvist, Lars Jacobsson, et al.
Cancer Biotherapy & Radiopharmaceuticals
|
December 13, 2012
Comparison of 211At-PRIT and 211At-RIT of ovarian microtumors in a nude mouse model
Sofia H L Frost, Tom Bäck, Nicolas Chouin, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
June 14, 2013
Ex vivo activity quantification in micrometastases at the cellular scale using the α-camera technique
Nicolas Chouin, Sture Lindegren, Sofia H L Frost, et al.
International Journal of Radiation Oncology, Biology, Physics
|
September 18, 2007
Therapeutic efficacy of astatine-211-labeled trastuzumab on radioresistant SKOV-3 tumors in nude mice
Stig Palm, Tom Bäck, Ingela Claesson, et al.
Cancer Biotherapy & Radiopharmaceuticals
|
June 14, 2012
Evaluation of effects on the peritoneum after intraperitoneal α-radioimmunotherapy with (211)At
Elin Cederkrantz, Eva Angenete, Tom Bäck, et al.
EJNMMI Research
|
April 26, 2017
Therapeutic efficacy of α-radioimmunotherapy with different activity levels of the <sup>213</sup>Bi-labeled monoclonal antibody MX35 in an ovarian cancer model
Anna Gustafsson-Lutz, Tom Bäck, Emma Aneheim, et al.
Nuclear Medicine and Biology
|
November 28, 2006
Fractionated radioimmunotherapy of intraperitoneally growing ovarian cancer in nude mice with 211At-MX35 F(ab')2: therapeutic efficacy and myelotoxicity
Jörgen Elgqvist, Håkan Andersson, Tom Bäck, et al.
Nuclear Medicine and Biology
|
October 1, 2011
Comparison of therapeutic efficacy and biodistribution of 213Bi- and 211At-labeled monoclonal antibody MX35 in an ovarian cancer model
Anna M E Gustafsson, Tom Bäck, Jörgen Elgqvist, et al.
Page
of 11
Search research articles
Search
Showing results (91-100 of 108) with videos related to
Sort By:
Page
of 11
Nordic Journal of Psychiatry
|
June 19, 2004
Coercion in psychiatric care - patients' and relatives' experiences from four Swedish psychiatric services
Lars Kjellin, Kristina Andersson, Erik Bartholdson, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
November 5, 2005
Therapeutic efficacy and tumor dose estimations in radioimmunotherapy of intraperitoneally growing OVCAR-3 cells in nude mice with (211)At-labeled monoclonal antibody MX35
Jörgen Elgqvist, Håkan Andersson, Tom Bäck, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
July 7, 2022
Estimating the Risk for Secondary Cancer After Targeted α-Therapy with <sup>211</sup>At Intraperitoneal Radioimmunotherapy
Erik Leidermark, Andreas Hallqvist, Lars Jacobsson, et al.
Cancer Biotherapy & Radiopharmaceuticals
|
December 13, 2012
Comparison of 211At-PRIT and 211At-RIT of ovarian microtumors in a nude mouse model
Sofia H L Frost, Tom Bäck, Nicolas Chouin, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
June 14, 2013
Ex vivo activity quantification in micrometastases at the cellular scale using the α-camera technique
Nicolas Chouin, Sture Lindegren, Sofia H L Frost, et al.
International Journal of Radiation Oncology, Biology, Physics
|
September 18, 2007
Therapeutic efficacy of astatine-211-labeled trastuzumab on radioresistant SKOV-3 tumors in nude mice
Stig Palm, Tom Bäck, Ingela Claesson, et al.
Cancer Biotherapy & Radiopharmaceuticals
|
June 14, 2012
Evaluation of effects on the peritoneum after intraperitoneal α-radioimmunotherapy with (211)At
Elin Cederkrantz, Eva Angenete, Tom Bäck, et al.
EJNMMI Research
|
April 26, 2017
Therapeutic efficacy of α-radioimmunotherapy with different activity levels of the <sup>213</sup>Bi-labeled monoclonal antibody MX35 in an ovarian cancer model
Anna Gustafsson-Lutz, Tom Bäck, Emma Aneheim, et al.
Nuclear Medicine and Biology
|
November 28, 2006
Fractionated radioimmunotherapy of intraperitoneally growing ovarian cancer in nude mice with 211At-MX35 F(ab')2: therapeutic efficacy and myelotoxicity
Jörgen Elgqvist, Håkan Andersson, Tom Bäck, et al.
Nuclear Medicine and Biology
|
October 1, 2011
Comparison of therapeutic efficacy and biodistribution of 213Bi- and 211At-labeled monoclonal antibody MX35 in an ovarian cancer model
Anna M E Gustafsson, Tom Bäck, Jörgen Elgqvist, et al.
Page
of 11